| First Author | Pino MV | Year | 2004 |
| Journal | Toxicol Pathol | Volume | 32 |
| Issue | 1 | Pages | 58-63 |
| PubMed ID | 14713549 | Mgi Jnum | J:88111 |
| Mgi Id | MGI:3029131 | Doi | 10.1080/01926230490261320 |
| Citation | Pino MV, et al. (2004) Promotion of Colon Tumors in C57BL/6J-APC(min)/+ Mice by Thiazolidinedione PPARgamma Agonists and a Structurally Unrelated PPARgamma Agonist. Toxicol Pathol 32(1):58-63 |
| abstractText | Thiazolidinedione PPARgamma agonists (troglitazone and rosiglitazone) were previously shown to promote colon tumor formation in C57BL/6J-APC(min)/+ mice, a model for human familial adenomatous polyposis. This study was conducted to determine if another thiazolidinedione PPARgamma agonist, pioglitazone, and a PPARgamma agonist structurally unrelated to the thiazolidinedione family, NID525, (a tetrazole-substituted phenoxymethylquinolone), would also promote colon tumors in this mouse model. Mice were treated in-feed with the thiazolidinediones troglitazone (150 mg/kg/day), rosiglitazone (20 mg/kg/day), or pioglitazone (150 mg/kg/day), or with NID525 (150 mg/kg/day) for 8 weeks. An increased incidence in colon tumors compared to controls was observed for all of the thiazolidinedione-treated groups as well as the NID525-treated group. These results indicate that the tumor-promoting effect of PPARgamma agonists in the colon of C57BL/6J-APC(min)/+ mice is likely related to the pharmacological activity of this group of drugs and not the thiazolidinedione structure. |
